Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus

Van Der Meeren, Olivier, Peterson, James T., Dionne, Marc, Beasley, Richard, Ebeling, Peter R., Ferguson, Murdo, Nissen, Michael D., Rheault, Paul, Simpson, Richard W., De Ridder, Marc, Crasta, Priya D., Miller, Jacqueline M. and Trofa, Andrew F. (2016) Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus. Human Vaccines and Immunotherapeutics, 12 8: 2197-2203. doi:10.1080/21645515.2016.1164362


Author Van Der Meeren, Olivier
Peterson, James T.
Dionne, Marc
Beasley, Richard
Ebeling, Peter R.
Ferguson, Murdo
Nissen, Michael D.
Rheault, Paul
Simpson, Richard W.
De Ridder, Marc
Crasta, Priya D.
Miller, Jacqueline M.
Trofa, Andrew F.
Title Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus
Journal name Human Vaccines and Immunotherapeutics   Check publisher's open access policy
ISSN 2164-554X
2164-5515
Publication date 2016-04-28
Year available 2016
Sub-type Article (original research)
DOI 10.1080/21645515.2016.1164362
Open Access Status DOI
Volume 12
Issue 8
Start page 2197
End page 2203
Total pages 7
Place of publication New York, NY, United States
Publisher Taylor & Francis
Collection year 2017
Language eng
Formatted abstract
Objective: Patients with diabetes mellitus are at increased risk for hepatitis B virus (HBV) infection and its complications. HBV vaccination is recommended for adults with diabetes in the United States and other countries. However, few studies have assessed safety and immunogenicity of hepatitis B vaccine in such patients. We assessed the safety and immunogenicity of recombinant hepatitis B vaccine in subjects with and without diabetes mellitus.

Methods: Prospective, multi-country controlled study in 21 centers (www.clinicaltrials.gov NCT01627340). Four hundred and sixteen participants with Type-2 diabetes and 258 controls matched for age and body mass index (BMI) (2:1 ratio) received 3-doses of HBV vaccine (Engerix-B™, GSK Vaccines, Belgium) according to a 0, 1, 6 months schedule. Antibodies were measured against HBV surface antigen and expressed as seroprotection rates (anti-HBs ≥10mIU/mL) and geometric mean concentration (GMC).

Results: The median age and BMI in patients with diabetes and controls (according-to-protocol cohort) were 54 y and 32.1 kg/m2, and 53 y and 30.8 kg/m2, respectively. Seroprotection rates (GMCs) one month post-dose-3 were 75.4% (147.6 mIU/mL) and 82.0% (384.2 mIU/mL) in patients with diabetes and controls, respectively. Age-stratified seroprotection rates for patients with diabetes were 88.5% (20–39 years), 81.2% (40–49 years), 83.2% (50–59 years), and 58.2% (≥60 years). The overall safety profile of hepatitis B vaccine was similar between groups.

Conclusions: Hepatitis B vaccine is immunogenic in patients with diabetes and has a similar safety profile to vaccination in healthy controls. Because increasing age was generally associated with a reduction in seroprotection rates, hepatitis B vaccine should be administered as soon as possible after the diagnosis of diabetes.
Keyword Clinical trial
Hepatitis B
Infections
Type-2 diabetes
Vaccination
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
Admin only - CHRC
Child Health Research Centre Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 24 May 2016, 00:55:55 EST by System User on behalf of Learning and Research Services (UQ Library)